Innovation and 
Our Pipeline

Roche-Genentech leads the industry in R&D investment with a world-class pipeline in Ophthalmology

Hero Image. Woman Doctor in PPE

Innovation and 
Our Pipeline

Roche-Genentech leads the industry in R&D investment with a world-class pipeline in Ophthalmology

Hero Image. Woman Doctor in PPE

Timeline of Genentech Medicine Approvals

Scroll to learn more about our 42 approved medicines and 33 FDA-granted breakthrough therapy designations.

26 medicine logos that Roche-Genentech have created and the years they were released to patients

Disclaimer: Some therapies have not been shown.

Couple hiking a mountain while smiling

One of the Strongest R&D Pipelines in the Industry

129 projects icon representing Genentechs projects in phase 1-3

projects in Phases I-III

67 molecules icon representing NMEs in devolopment

new molecular entities (NMEs) in
development

6 plus icon representing the disease categories Genentech works on

disease categories such as
cardiometabolism, neuroscience,
oncology, ophthalmology,
immunology, infectious diseases, and others 

Step into the future with Genentech Ophthalmology

Our 2021 Ophthalmology Pipeline Highlights

We have the broadest late-stage retina pipeline, including treatments for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and macular edema following retinal vein occlusion (RVO). Our robust, early-stage pipeline also includes gene therapies and treatments for geographic atrophy (GA).

Click to learn more about Ang-2 and its ability to inhibit the Ang-Tie pathway

Ang-2=angiopoietin-2; Ang-Tie=angiopoietin-Tie.